Ascendis reclaims Novo Nordisk rights in diabetes and obesity push
The biotech says regaining the programs supports its own cardiometabolic development strategy.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 15 03:05 ETSource: medwatch.com
The wire
- 01Ascendis Pharma took back diabetes and obesity rights previously licensed to Novo Nordisk.
- 02Repositions Ascendis as an independent player in crowded cardiometabolic development.
- 03Timing of trials and any new partners have not been disclosed.
From the source
Read at news.google.comAscendis Pharma takes back rights from Novo Nordisk in diabetes and obesity push